ReviewOncotarget2017
Strategies targeting angiogenesis in advanced non-small cell lung cancer.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Article
- Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.Archives of pharmacal research · 2022Review
- Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects.Frontiers in pharmacology · 2022Review
- Lung Pericytes in Pulmonary Vascular Physiology and Pathophysiology.Comprehensive Physiology · 2021Article
- MicroRNA-126: A new and promising player in lung cancer.Oncology letters · 2021Review
- Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma.Pathology oncology research : POR · 2020Article
- New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.Journal of cancer research and clinical oncology · 2020Review
- Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.Therapeutic advances in medical oncology · 2020Review
- Gemcitabine Combination Nano Therapies for Pancreatic Cancer.Pharmaceutics · 2019Review
- Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer.Oncology letters · 2019Article
- Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.Autophagy · 2019Article
- The Biological-Behavioral Effect Of Neuritin On Non-Small Cell Lung Cancer Vascular Endothelial Cells Via VEGFR And Notch1.OncoTargets and therapy · 2019Article
- The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients.Journal of Cancer · 2019Article
- Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation EffectTheranostics · 2019Article
- [Research Advances of Ang-2 in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.Journal of thoracic disease · 2018Article
- Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.British journal of cancer · 2018Article
- TIE2-expressing monocytes and M2-polarized macrophages impact survival and correlate with angiogenesis in adenocarcinoma of the pancreas.Oncotarget · 2018Article
- Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells.Oncotarget · 2018Article
- Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.Cell death & disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor angiogenesis is a frequent event in the development and progression of non-small cell lung cancer (NSCLC) and has been identified as a promising therapeutic target. The vascular endothelial growth factor (VEGF) family and other angiogenic factors, including fibroblast growth factor and platelet-derived growth factor, promote the growth of newly formed vessels from preexisting vessels and change the tumor microenvironment. To date, two antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab, which target VEGF-A and its receptor VEGF receptor-2, respectively, have been approved for the treatment of locally advanced or metastatic NSCLC when added to first-line standard chemotherapy. Numerous oral multitargeting angiogenic small molecule tyrosine kinase inhibitors (TKIs) have been widely evaluated in advanced NSCLC, but only nintedanib in combination with platinum-based doublet chemotherapy has demonstrated a survival benefit in the second-line setting. Additionally, small-molecule TKIs remain the standard of care for patients with mutated EGFR, ALK or ROS1. Moreover, immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) are changing the current strategy in the treatment of advanced NSCLC without driver gene mutations. The potential synergistic activity of antiangiogenic agents and TKIs or immunotherapy is an interesting topic of research. This review will summarize the novel antiangiogenic agents, antiangiogenic monotherapy, as well as potential combination therapeutic strategies for the clinical management of advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.